NIHR

New Gene-Expression Patterns Linked to Schizophrenia, Bipolar Disorder and Major Depressive Disorder, New Study Shows

Retrieved on: 
星期三, 五月 22, 2024
Mental Health, Health, Genetics, Science, Research, Patient, Bangladesh Technical Education Board, Doctor of Philosophy, TWAS, Gene expression, Hope, Disorder, Medical research, Nature Communications, Depression, NIHR, DSM-IV codes, Disease, Infection, Genome, Mental disorder, Inflammation, Schizophrenia, Bipolar disorder, Multimedia, NIH, Pharmaceutical industry

Through advanced transcriptome-wide association studies (TWAS), researchers can identify unique gene expression profiles to identify new drug targets to treat these disorders.

Key Points: 
  • Through advanced transcriptome-wide association studies (TWAS), researchers can identify unique gene expression profiles to identify new drug targets to treat these disorders.
  • Today, results from a study published by researchers at The Feinstein Institutes for Medical Research and King’s College London in Nature Communications reveal new gene expression patterns linked to common mental health disorders, providing a roadmap for future therapeutic research.
  • Human endogenous retroviruses (HERVs) are non-coding sequences that make up about eight percent of the human genome.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

ERS Genomics Appoints John E Milad as Chief Executive Officer

Retrieved on: 
星期一, 五月 13, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Health Technology, Genetics, Quanta, ACT, Yeast, Patient, Cas9, Atlas Venture, Synthetic biology, Gene editing, Emmanuelle, Patent, Royal Academy of Arts, CFO, Investment, University, NIHR, Bacteria, Nobel Prize, Royal, Partner, Archaea, WebMD, ERS, Cell, Genomics, CRISPR, Atlas, Prokaryote, Agriculture, Entrepreneurship, Pharmaceutical industry

ERS Genomics Limited (‘ERS’), the CRISPR licensing company, today announced the appointment of John E Milad as CEO, with immediate effect.

Key Points: 
  • ERS Genomics Limited (‘ERS’), the CRISPR licensing company, today announced the appointment of John E Milad as CEO, with immediate effect.
  • John brings over 25 years of experience as an executive leader, venture capitalist, and investment banker focused on the life sciences and medical technology sectors.
  • Shaun Foy, Co-Founder and Chair of the Board of Directors, ERS Genomics, commented: “On behalf of the Board and executive team, I would like to welcome John as CEO.
  • ERS Genomics licenses these patents via its direct license from Emmanuelle Charpentier and now has nearly 150 licenses in place worldwide.

Trevi Therapeutics to Participate in Upcoming Conferences

Retrieved on: 
星期四, 五月 9, 2024
Corporation, Idiopathic pulmonary fibrosis, University, NIHR, NHS foundation trust, IPF, Respiratory Medicine, Doctor of Philosophy, MB, Chronic cough, University of Manchester, Panel, RCC, FRCP, Therapy, Management

Corporate Presentation: May 14 at 12:00 p.m.

Key Points: 
  • Corporate Presentation: May 14 at 12:00 p.m.
  • ET
    Presenter: Jacky Smith, MB, ChB, FRCP, PhD, Professor of Respiratory Medicine at the University of Manchester, and an Honorary Consultant at Manchester University NHS Foundation Trust.
  • Director of the NIHR Manchester Clinical Research Facility, Respiratory Theme Lead in the NIHR Manchester Biomedical Research Centre and an NIHR Senior Investigator.
  • Panel Members: Experts in the field of chronic cough include Professor Peter Dicpinigaitis, Professor Jacky Smith, and Professor Alyn Morice.

Eye2Gene and Heidelberg Engineering Announce Collaborative Partnership at ARVO 2024

Retrieved on: 
星期二, 五月 7, 2024
Research, General Health, Optical, Apps, Applications, Medical Devices, Technology, Artificial Intelligence, Genetics, Science, Other Technology, Other Science, Health, Retina, AI, NIHR, Partnership, Artificial intelligence, Similarity, Infrared, OCT, Patient, DSM-IV codes, Data set, Annual general meeting, Medicine, Moorfields Eye Hospital, ARVO, Deep learning

Eye2Gene™ , a pioneering artificial intelligence National Institute for Health and Care Research (NIHR) funded project based at the University College London Institute of Ophthalmology and Moorfields Eye Hospital, and Heidelberg Engineering , a global leader in ophthalmic imaging and data technologies, are thrilled to announce their collaborative partnership, set to be unveiled at the ARVO 2024 Annual Meeting in Seattle.

Key Points: 
  • Eye2Gene™ , a pioneering artificial intelligence National Institute for Health and Care Research (NIHR) funded project based at the University College London Institute of Ophthalmology and Moorfields Eye Hospital, and Heidelberg Engineering , a global leader in ophthalmic imaging and data technologies, are thrilled to announce their collaborative partnership, set to be unveiled at the ARVO 2024 Annual Meeting in Seattle.
  • By combining Eye2Gene's cutting-edge artificial intelligence algorithm with Heidelberg Engineering image quality and innovative workflow solutions, the partnership aims to revolutionize the care pathway for patients with inherited retinal disease.
  • At ARVO 2024, attendees can experience firsthand the power of this collaboration at Stand #1905 and learn more about the collaborative partnership between Eye2Gene and Heidelberg Engineering.
  • "Because inherited diseases are rare, they are challenging to diagnose for most non-specialists," said Nikolas Pontikos, lead researcher for Eye2Gene.

Sibel Health awarded a major grant to advance maternal monitoring solution for low-and-middle income countries.

Retrieved on: 
星期二, 四月 23, 2024
Mortality, FDA, University, UN, University of Edinburgh, Tech, NIH, Risk, Woman, Pregnancy, NIHR, Health, Consultant, Death, Data science, Maternal health, Vital signs, Partnership, Acceleration, Transplant surgeon, Guinness World Records, Entrepreneurship, Guinness, Patient, Bill, Melinda French Gates, Royal, Royal Infirmary of Edinburgh, Medical device

CHICAGO, April 23, 2024 /PRNewswire/ -- Sibel Health, an award-winning health technology company backed by the Steele Foundation for Hope , announced it has received a $17.5 million dollar grant from the Bill & Melinda Gates Foundation to advance the use of its FDA-cleared wireless monitoring solution, ANNE® One, for labor triage and continuous maternal health monitoring in low-and-middle income countries (LMICs) to reduce obstetrical morbidity and mortality.

Key Points: 
  • CHICAGO, April 23, 2024 /PRNewswire/ -- Sibel Health, an award-winning health technology company backed by the Steele Foundation for Hope , announced it has received a $17.5 million dollar grant from the Bill & Melinda Gates Foundation to advance the use of its FDA-cleared wireless monitoring solution, ANNE® One, for labor triage and continuous maternal health monitoring in low-and-middle income countries (LMICs) to reduce obstetrical morbidity and mortality.
  • "Sibel Health was spun out of Northwestern University and founded from an initial grant from the Bill & Melinda Gates Foundation given our commitment to maternal neonatal health.
  • Vital signs are vital—and every pregnant person deserves to have their vitals checked," said Steve Xu MD, CEO and Co-Founder of Sibel Health.
  • Most recently, the Gates Foundation has invested more than $100 million dollars in bringing point of care ultrasound to LMICs for maternal health.

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference

Retrieved on: 
星期二, 四月 9, 2024
MB, NHS foundation trust, Conference, ATS, NIHR, University of Manchester, University, Doctor of Philosophy, Respiratory Medicine, American Thoracic Society, Chronic cough, FRCP, IPF, Idiopathic pulmonary fibrosis, RCC, Therapy

NEW HAVEN, Conn., April 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2 CANAL trial will be presented at the American Thoracic Society (ATS) 2024 International Conference being held in San Diego, CA, from May 17-22. The presentation will take place on May 19th.

Key Points: 
  • NEW HAVEN, Conn., April 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2 CANAL trial will be presented at the American Thoracic Society (ATS) 2024 International Conference being held in San Diego, CA, from May 17-22.
  • The presentation will take place on May 19th.
  • Presenter: Jacky Smith, MB, ChB, FRCP, PhD, Professor of Respiratory Medicine at the University of Manchester, and an Honorary Consultant at Manchester University NHS Foundation Trust.
  • Director of the NIHR Manchester Clinical Research Facility, Respiratory Theme Lead in the NIHR Manchester Biomedical Research Centre and an NIHR Senior Investigator.

GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom

Retrieved on: 
星期一, 三月 4, 2024
Oxygen, IPF, Idiopathic disease, Serum, Doctor of Philosophy, Blood, Homeostasis, Idiopathic pulmonary fibrosis, Inflammation, Vital signs, Safety, Health care, BAL, Biomarker, Pharmacokinetics, Patient, NKT, Natural killer T cell, Bronchoalveolar lavage, NIHR, Movement, GRI, CTA, Immune system, Pharmaceutical industry

LA JOLLA, CA, March 04, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF in the UK.

Key Points: 
  • The MHRA is the UK regulatory authority, a government agency, for medicines and medical devices.
  • The MHRA is responsible for the regulation of medicines and medical devices and equipment used in healthcare and the investigation of harmful incidents.
  • “We are pleased to receive authorization from the MHRA and take a step in the global expansion of our clinical development for GRI-0621.
  • We are focused on driving this program forward and generating important data readouts this year,” Marc Hertz, PhD, Chief Executive Officer of GRI Bio.

CEL-SCI Corporation Issues Letter to Shareholders

Retrieved on: 
星期三, 三月 6, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Head, Neck, EMA, Health Canada, ESMO, Condition, Neoadjuvant therapy, Plasma protein binding, Neoplasm, Immunotherapy, Physician, Marketing, SCCHN, FDA, Food, BLA, Letter, Risk, European, Patent, COVID, Patient, Policy, MHRA, NOCC, United, Survival, Congress, NIHR, Diagnosis, Pembrolizumab, CGMP, PD-L1, Radiation, Pharmaceutical industry

CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.

Key Points: 
  • CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.
  • This letter will be sent to the Company’s shareholders along with the proxy to the upcoming annual meeting.
  • In October 2023, the new data were presented at the 2023 European Society for Medical Oncology (ESMO) Congress.
  • These features make it easy to write a label for Multikine, which is essential for drug approval.

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results

Retrieved on: 
星期四, 二月 15, 2024
Oncology, Health, FDA, Manufacturing, Clinical Trials, Other Manufacturing, Pharmaceutical, Head, Neck, EMA, Health Canada, ESMO, Condition, Neoadjuvant therapy, Physician, Marketing, SCCHN, Food, BLA, Risk, European, Patient, Policy, United, NOCC, Congress, NIHR, Diagnosis, Corporation, Research, Plasma protein binding, Pharmaceutical industry

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2023, as well as key recent clinical and corporate developments.

Key Points: 
  • CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2023, as well as key recent clinical and corporate developments.
  • In October 2023, the new data were presented at the 2023 European Society for Medical Oncology (ESMO) Congress.
  • CEL-SCI plans to submit the target population data to the U.S. Food and Drug Administration (FDA) this quarter.
  • CEL-SCI raised $5 million in November 2023 and $7.75 million in February 2024, both through public offerings of common stock.

RTW Charitable Foundation Announces Six Research Grant Recipients

Retrieved on: 
星期一, 二月 12, 2024
Biotechnology, Health, Philanthropy, Pharmaceutical, Neurology, Research, Fund Raising, Genetics, Foundation, Science, Clinical Trials, Therapy, RTW, University College London, Grant (money), Metabolism, Toxicity, Doctor of Philosophy, IRF2BPL, Nationwide, University, Gene, Nonprofit organization, Growth, Hospital, Life, Weakness, Translation, University of California, Patient, NIHR, Child, AAV, Kidney transplantation, Kidney failure, Pharmaceutical industry

RTW Charitable Foundation (“RTWCF”) announced today that it has awarded $900,000 in research grants to support six research studies.

Key Points: 
  • RTW Charitable Foundation (“RTWCF”) announced today that it has awarded $900,000 in research grants to support six research studies.
  • “Optimizing AAV-SPL gene therapy for sphingosine phosphate lyase insufficiency syndrome” (Julie Saba, University of California, San Francisco, San Francisco, CA).
  • “RTW Charitable Foundation is proud to provide financial and scientific support to these six incredible researchers and their respective studies.
  • In addition to delivering financial resources, RTWCF also provides grant recipients with hands-on scientific support, helping them improve or further develop their research and research tools and identify new therapeutic targets.